Measures · D08 in 2027 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Diabetes Medications
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- The percentage of plan members with a prescription for diabetes medication who fill their prescription often enough to cover 80% or more of the time they are taking the medication. One of the most important ways people with diabetes can manage their health is by taking their medication. The plan, the doctor, and the member can work together to find ways to do this. (“Diabetes medication” means a biguanide drug, a sulfonylurea drug, a thiazolidinedione drug, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist, a meglitinide drug, or a sodium glucose cotransporter 2 (SGLT2) inhibitor.)
- How it's calculated
- This measure is defined as the percentage of Medicare Part D beneficiaries, 18 years and older, who adhere to their prescribed drug therapy across classes of diabetes medications: biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GIP/GLP-1 receptor agonists, meglitinides, and SGLT2 inhibitors. The proportion of days covered (PDC) is the percentage of days in the treatment period “covered” by prescription claims for the same medication or another in its therapeutic category. The index prescription start date (IPSD) is the earliest date of service for a target medication during the measurement year. The treatment period begins on the IPSD and extends through whichever comes first: the last day of enrollment during the measurement year, death, or the end of the measurement year. The treatment period must be at least 91 days during the measurement year. Continuous enrollment (CE) is defined as being continuously enrolled in a Medicare Part D contract during the treatment period with no enrollment gaps allowed during the treatment period. This percentage is calculated as the number of continuously enrolled Medicare Part D beneficiaries, 18 years and older, with a PDC of 80 percent or higher across the classes of diabetes medications during the treatment period (numerator) divided by the number of continuously enrolled beneficiaries, 18 years and older, with at least two fills of diabetes medication(s) on unique dates of service during the treatment period, and a treatment period that is at least 91 days during the measurement year (denominator). The Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). See the medication list for this measure. The Medication Adherence rate is calculated using the National Drug Code (NDC) list maintained by the PQA. The complete NDC list, including diagnosis codes, is posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from PDE data submitted by drug plans to CMS Drug Data Processing Systems (DDPS) and accepted by the 2025 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2025- December 31, 2025. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2025 PDE submission deadline are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for diabetes medication(s). PDE adjustments made post-reconciliation are not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Common Working File (CWF), and the Encounter Data Systems (EDS). The data cutoff date for all the additional data sources listed below such as the CME, CWF, and EDS is determined by the same PDE submission deadline for the annual Part D payment reconciliation. • CME is used for enrollment information and to identify beneficiaries who elected to receive hospice care or with ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes (on inpatient, outpatient, or carrier claims), inpatient (IP) and skilled nursing facility (SNF) stays for PDPs and MA-PDs (if available). • EDS is used to identify exclusion diagnoses based on ICD-10-CM codes (on inpatient, outpatient, or carrier claims), and SNF/IP stays for MA-PD beneficiaries.
- Measurement period
- 01/01/2025 – 12/31/2025
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 29 or fewer continuously enrolled beneficiaries (in the denominator). The following beneficiaries are also excluded from the denominator if at any time during the measurement period unless otherwise specified: • In hospice • ESRD diagnosis or dialysis coverage dates • One or more prescriptions for insulin in the treatment period- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. The PDC calculation is adjusted for overlapping prescriptions for the same drug, which is defined by the active ingredient at the generic name level using the NDC list maintained by PQA. The calculation also adjusts for Part D beneficiaries’ stays in IP settings and stays in SNFs. The discharge date is included as an adjustment for IP/SNF stays. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s treatment period.
- Disaster policy
- Higher measure star (2026-2027) for contracts with 25% or more enrolled affected by 2025 disasters.
From the 2027 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 86 | 88 | +2 |
| 3★ | MA-PD | 89 | 90 | +1 |
| 4★ | MA-PD | 91 | 92 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 86 | 86 | 0 |
| 3★ | PDP | 88 | 88 | 0 |
| 4★ | PDP | 90 | 90 | 0 |
| 5★ | PDP | 95 | 95 | 0 |
2027 star distribution
Not rated: Plan too new to be measured (94); Not enough data available (29); Plan not required to report measure (8)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2027 | PDP | < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 95 % | >= 95 % |
| 2026 | MA-PD | < 83 % | >= 83 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 92 % | >= 92 % |
| 2026 | PDP | < 85 % | >= 85 % to < 87 % | >= 87 % to < 89 % | >= 89 % to < 92 % | >= 92 % |
| 2025 | MA-PD | < 80 % | >= 80 % to < 85 % | >= 85 % to < 87 % | >= 87 % to < 91 % | >= 91 % |
| 2025 | PDP | < 85 % | >= 85 % to < 87 % | >= 87 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2024 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2024 | PDP | < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2023 | MA-PD | < 79 % | >= 79 % to < 85 % | >= 85 % to < 88 % | >= 88 % to < 92 % | >= 92 % |
| 2023 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2022 | MA-PD | < 80 % | >= 80 % to < 85 % | >= 85 % to < 87 % | >= 87 % to < 91 % | >= 91 % |
| 2022 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2021 | MA-PD | < 76 % | >= 76 % to < 80 % | >= 80 % to < 84 % | >= 84 % to < 88 % | >= 88 % |
| 2021 | PDP | < 79 % | >= 79 % to < 82 % | >= 82 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2020 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2020 | PDP | < 79% | ? 79% to < 83% | ? 83% to < 85% | ? 85% to < 88% | ? 88% |
| 2019 | MA-PD | < 72% | ? 72% to < 78% | ? 78% to < 81% | ? 81% to < 85% | ? 85% |
| 2019 | PDP | < 82% | ? 82% to < 84% | ? 84% to < 86% | ? 86% to < 88% | ? 88% |
| 2018 | MA-PD | < 72% | ? 72% to < 78% | ? 78% to < 81% | ? 81% to < 86% | ? 86% |
| 2018 | PDP | < 76% | ? 76% to < 80% | ? 80% to < 84% | ? 84% to < 86% | ? 86% |
| 2017 | MA-PD | < 70% | ? 70% to < 76% | ? 76% to < 79% | ? 79% to < 83% | ? 83% |
| 2017 | PDP | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 86% | ? 86% |
| 2016 | MA-PD | < 60% | ? 60% to < 69% | ? 69% to < 75% | ? 75% to < 82% | ? 82% |
| 2016 | PDP | < 75% | ? 75% to < 80% | ? 80% to < 83% | ? 83% to < 95% | ? 95% |
| 2015 | MA-PD | < 69% | ? 69% to < 73% | ? 73% to < 77% | ? 77% to < 81% | ? 81% |
| 2015 | PDP | < 74% | ? 74% to < 79% | ? 79% to < 82% | ? 82% to < 85% | ? 85% |
Lowest-scoring contracts, 2027
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H8332 Aetna Medicare | CVS Health Corporation | 197 | 76 | 1 | −1 | 15 | 0% |
| S0375 CareFirst BlueCross BlueShield Group Prescription Drug Plan | CareFirst, Inc. | 549 | 84 | 1 | — | 6 | 0% |
| H9066 Nascentia Health Plus | VISITING NURSE ASSOCIATION OF CENTRAL NEW YORK | 663 | 76 | 1 | 0 | 15 | 0% |
| H3551 eternalHealth | Eternal Health of Delaware, Inc. | 2,467 | 77 | 1 | −1 | 14 | 0% |
| H8879 Healthy Mississippi, Inc. | Singh Holdings LLC | 500 | 79 | 1 | — | 12 | 1% |
| H6959 KeyCare Advantage | ISNP Holdings, LLC | 538 | 80 | 1 | −2 | 11 | 1% |
| H0738 AmeriHealth Caritas VIP Care (HMO-D-SNP) | Independence Health Group, Inc. | 1,048 | 80 | 1 | — | 11 | 1% |
| H2185 Lifeworks Advantage | Curana Health Holdings, LLC | 314 | 80 | 1 | −1 | 11 | 1% |
| H3928 Aetna Medicare | CVS Health Corporation | 4,912 | 81 | 1 | 0 | 10 | 1% |
| H4676 Troy Medicare | Troy Holdings, Inc. | 1,654 | 81 | 1 | 0 | 10 | 1% |
| H0270 Wellcare | Centene Corporation | 631 | 81 | 1 | −2 | 10 | 1% |
| H2926 PrimeWest Health | PrimeWest Rural MN Health Care Access Initiative | 749 | 81 | 1 | −2 | 10 | 1% |
| H1947 Healthy Blue | Elevance Health, Inc. | 3,486 | 82 | 1 | −1 | 9 | 2% |
| H4490 American Health Advantage of Missouri | Mitchell Family Office | 832 | 82 | 1 | −1 | 9 | 2% |
| H9460 HealthSpring | Health Care Service Corporation | 1,325 | 82 | 1 | 0 | 9 | 2% |
| H3814 ATRIO Health Plans | ATRIO Health Plans | 1,997 | 82 | 1 | 0 | 9 | 2% |
| H9431 Aetna Medicare | CVS Health Corporation | 666 | 82 | 1 | −2 | 9 | 2% |
| S5966 EmblemHealth | EmblemHealth, Inc. | 105,012 | 85 | 1 | 0 | 5 | 2% |
| S5795 Arkansas Blue Medicare | USAble Mutual Insurance Company | 19,195 | 85 | 1 | −1 | 5 | 2% |
| H9147 Blue Cross and Blue Shield of North Carolina | CuraCor Solutions Corp. | 3,516 | 83 | 1 | −2 | 8 | 3% |
| H0074 Wellcare | Centene Corporation | 1,451 | 83 | 1 | −2 | 8 | 3% |
| H3407 El Paso Health Medicare Advantage | El Paso County Hospital District | 2,178 | 83 | 1 | −1 | 8 | 3% |
| H5435 UnitedHealthcare | UnitedHealth Group, Inc. | 1,420 | 83 | 1 | −1 | 8 | 3% |
| H6345 PruittHealth Premier | UNICO Services, Inc. | 882 | 83 | 1 | −2 | 8 | 3% |
| H5475 Wellcare | Centene Corporation | 18,951 | 83 | 1 | 0 | 8 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D08 | Medication Adherence for Diabetes Medications | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D08 | Medication Adherence for Diabetes Medications | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D08 | Medication Adherence for Diabetes Medications | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D08 | Medication Adherence for Diabetes Medications | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D08 | Medication Adherence for Diabetes Medications | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D08 | Medication Adherence for Diabetes Medications | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D10 | Medication Adherence for Diabetes Medications | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D10 | Medication Adherence for Diabetes Medications | 01/01/2018 – 12/31/2018 | — | Prescription Drug Events |
| 2019 | D10 | Medication Adherence for Diabetes Medications | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D11 | Medication Adherence for Diabetes Medications | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D12 | Medication Adherence for Diabetes Medications | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D12 | Medication Adherence for Diabetes Medications | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D11 | Medication Adherence for Diabetes Medications | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |